Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/07/20
End: 12/31/25
Due: 12/31/26
IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
Phase: N/A
Priority: Normal
Start: 05/06/23
End: 08/15/24
Due: 08/15/25
Phase: N/A
Priority: Normal
Start: 06/01/21
End: 12/31/26
Due: 12/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | NCT04395677 | AnHeart Therapeutics Inc. | user2@example.com | None | 2020-07-07 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor | NCT05814536 | AnHeart Therapeutics Inc. | user2@example.com | None | 2023-05-06 | 2024-08-15 | 2025-08-15 | - | - | 2025-07-14 |
| Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene | NCT04617054 | AnHeart Therapeutics Inc. | user2@example.com | None | 2021-06-01 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |